Disrupted Glucose Metabolism in Irritable Bowel Syndrome: Targeting a Personalized Low-Glycemic Diet as a Potential Treatment Approach
-
By
-
May 1, 2026
Objective:
To investigate the therapeutic potential of a personalized low-glycemic diet (PLGD) in managing irritable bowel syndrome (IBS) and its impact on glucose metabolism, particularly focusing on individual glycaemic responses.
Key Findings:
- PLGD achieved a significant reduction in IBS Severity Scoring System (IBS-SSS) scores, comparable to LFD, with additional context on existing literature.
- Patients on PLGD showed a −100 point reduction in IBS-SSS (p=0.0195), indicating a clinically relevant improvement.
- The mechanistic basis for targeting glucose metabolism in IBS is supported by evidence of gut-brain axis dysregulation and shared pathophysiological features with type 2 diabetes.
Interpretation:
The findings suggest that targeting glucose metabolism through a personalized dietary approach can provide symptomatic relief in IBS, emphasizing the importance of individual glycaemic responses and their impact on IBS symptoms.
Limitations:
- The study involved a small sample size of 20 patients, which may limit generalizability.
- Further research is needed to validate the long-term efficacy and safety of PLGD, considering potential biases in observational studies.
Conclusion:
PLGD may represent a paradigm shift in IBS management, offering therapeutic benefits comparable to established treatments while addressing limitations of traditional dietary interventions, thus warranting further investigation.
